CJC-1295 with DAC
Aliases: CJC-1295 DAC · Drug Affinity Complex
Last verified: 2026-09-23
The short version
CJC-1295 with DAC is a long-acting GHRH analog that raised GH and IGF-1 ~1.5–3x in human trials with acceptable tolerability. Yet the program never became an approved drug — GHRH-pathway biopharma development stalled mid-way, partly due to competition from oral and peptide alternatives. Gray use is widespread, but long-term data do not exist.
Identity & type
- Molecular type
- analog
- Sequence / structure
- Modifikovan GHRH(1–29) + DAC komponenta
- Molecular weight
- ~3368 Da
- Origin
- Growth hormone-releasing hormone (GHRH) analog with an albumin-binding Drug Affinity Complex that extends half-life.
Mechanism of action
GHRH receptor agonist in the pituitary; DAC modification prevents rapid DPP-4 degradation enabling sustained GH stimulation.
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Commonly 1–2 mg SC once or twice weekly. With DAC: convenient 1–2× weekly dosing, steady mild GH/IGF-1 rise; the community reports better sleep, recovery and mild recomp. Water retention and numbness are more common than with the no-DAC version.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
With DAC: convenient 1–2× weekly dosing, steady mild GH/IGF-1 rise; the community reports better sleep, recovery and mild recomp. Water retention and numbness are more common than with the no-DAC version.
Protocol — official vs community
Official / label
No approved product. Clinical study: 30–60 mcg/kg SC weekly or biweekly (DAC extends half-life to ~6–8 days).
Duration: Study-defined single or repeated dosing.
The DAC (Drug Affinity Complex) makes it a long-acting GHRH analogue — one injection covers a week.
Community (anecdotal)
1–2 mg SC once or twice weekly (DAC half-life).
- Cycle:
- 8–12 weeks.
- Break:
- 4 weeks off.
Sustained GH/IGF-1 elevation from DAC versions is closer to pharmacological than physiological — some prefer no-DAC for that reason.
Human evidence
Phase I/II studies in adults (Teichman et al.) showed dose-dependent increases in GH and IGF-1 over several weeks; no large studies with clinical endpoints.
Preclinical evidence
ConjuChem ran Phase II; data show 2–10× GH/IGF-1 elevation lasting a week after a single dose. Development halted.
Known risks
- Theoretical injection-site lipohyperplasia (classic for DAC analogs)theoretical
- Water retention, joint pain at high dosescharacterized
- Long-term GH-pathway risks unknowncharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety
- Clinical benefit vs approved alternatives
Frequently asked questions
References
- Teichman S.L. et al., once-daily CJC-1295 in healthy adults (J Clin Endocrinol Metab, 2006)